CardioVax is a Los Angeles based biotechnology company focusing on immunotherapies for cardiovascular disease. The company has evolved from innovative discoveries at the Lund University Hospital in Malmö and Cedars-Sinai Medical Center.
We are developing immune therapies to treat cardiovascular disease, the number one cause of death globally. CardioVax therapies build protection against the accumulation of plaque within the walls of blood vessels which is responsible for most heart attacks and strokes.
Our products in preclinical development include an injectable vaccine, a mucosal vaccine, and an autologous cellular immunotherapy (a treatment using the patient's own cells). Each of these technologies is being optimized in the laboratory so that they will be safe for human trials.